JP2012508225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508225A5 JP2012508225A5 JP2011535189A JP2011535189A JP2012508225A5 JP 2012508225 A5 JP2012508225 A5 JP 2012508225A5 JP 2011535189 A JP2011535189 A JP 2011535189A JP 2011535189 A JP2011535189 A JP 2011535189A JP 2012508225 A5 JP2012508225 A5 JP 2012508225A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- solvate
- chlorophenyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 2-ethoxyphenyl Chemical group 0.000 claims 38
- 150000003839 salts Chemical class 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- LQZMJOXFUVVDCT-UHFFFAOYSA-N 1-(4-chlorobenzoyl)-3-[[4-(5-chloropyridin-2-yl)phenoxy]methyl]pyrrolidine-3-carboxylic acid Chemical compound C1CN(C(=O)C=2C=CC(Cl)=CC=2)CC1(C(=O)O)COC(C=C1)=CC=C1C1=CC=C(Cl)C=N1 LQZMJOXFUVVDCT-UHFFFAOYSA-N 0.000 claims 1
- GWFGOMUHMOMGLT-UHFFFAOYSA-N 1-(4-chlorobenzoyl)-3-[[6-(4-chlorophenyl)pyridin-3-yl]oxymethyl]pyrrolidine-3-carboxylic acid Chemical compound C1CN(C(=O)C=2C=CC(Cl)=CC=2)CC1(C(=O)O)COC(C=N1)=CC=C1C1=CC=C(Cl)C=C1 GWFGOMUHMOMGLT-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- CHYUFOTYYMEOMN-UHFFFAOYSA-N 3-[[2-(4-chlorophenyl)pyrimidin-5-yl]oxymethyl]-1-(4-fluorobenzoyl)pyrrolidine-3-carboxylic acid Chemical compound C1CN(C(=O)C=2C=CC(F)=CC=2)CC1(C(=O)O)COC(C=N1)=CN=C1C1=CC=C(Cl)C=C1 CHYUFOTYYMEOMN-UHFFFAOYSA-N 0.000 claims 1
- NOZQXHYQSNSPQM-UHFFFAOYSA-N 3-[[4-(4-cyanophenyl)phenoxy]methyl]-1-(4-fluorobenzoyl)pyrrolidine-3-carboxylic acid Chemical compound C1CN(C(=O)C=2C=CC(F)=CC=2)CC1(C(=O)O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=C1 NOZQXHYQSNSPQM-UHFFFAOYSA-N 0.000 claims 1
- MDVYCLAYSVNYDS-UHFFFAOYSA-N 3-[[4-(4-cyanophenyl)phenoxy]methyl]-1-(4-methoxybenzoyl)pyrrolidine-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1CC(COC=2C=CC(=CC=2)C=2C=CC(=CC=2)C#N)(C(O)=O)CC1 MDVYCLAYSVNYDS-UHFFFAOYSA-N 0.000 claims 1
- CAWFSRFUTWSXOX-UHFFFAOYSA-N 3-[[4-(5-chloropyrimidin-2-yl)phenoxy]methyl]-1-(2-methoxybenzoyl)pyrrolidine-3-carboxylic acid Chemical compound COC1=CC=CC=C1C(=O)N1CC(COC=2C=CC(=CC=2)C=2N=CC(Cl)=CN=2)(C(O)=O)CC1 CAWFSRFUTWSXOX-UHFFFAOYSA-N 0.000 claims 1
- XCKLZUHUUMODBH-UHFFFAOYSA-N 3-[[4-(5-chloropyrimidin-2-yl)phenoxy]methyl]-1-(4-fluorobenzoyl)pyrrolidine-3-carboxylic acid Chemical compound C1CN(C(=O)C=2C=CC(F)=CC=2)CC1(C(=O)O)COC(C=C1)=CC=C1C1=NC=C(Cl)C=N1 XCKLZUHUUMODBH-UHFFFAOYSA-N 0.000 claims 1
- SZCOBVONASAEKD-UHFFFAOYSA-N 3-[[4-(5-chloropyrimidin-2-yl)phenoxy]methyl]-1-(4-methoxybenzoyl)pyrrolidine-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1CC(COC=2C=CC(=CC=2)C=2N=CC(Cl)=CN=2)(C(O)=O)CC1 SZCOBVONASAEKD-UHFFFAOYSA-N 0.000 claims 1
- CJJSETSNHOWLJH-UHFFFAOYSA-N 3-[[4-(5-cyanopyridin-2-yl)phenoxy]methyl]-1-(4-fluorobenzoyl)pyrrolidine-3-carboxylic acid Chemical compound C1CN(C(=O)C=2C=CC(F)=CC=2)CC1(C(=O)O)COC(C=C1)=CC=C1C1=CC=C(C#N)C=N1 CJJSETSNHOWLJH-UHFFFAOYSA-N 0.000 claims 1
- UUAMAFWXTRITEN-UHFFFAOYSA-N 3-[[6-(4-chlorophenyl)pyridin-3-yl]oxymethyl]-1-(2-methoxybenzoyl)pyrrolidine-3-carboxylic acid Chemical compound COC1=CC=CC=C1C(=O)N1CC(COC=2C=NC(=CC=2)C=2C=CC(Cl)=CC=2)(C(O)=O)CC1 UUAMAFWXTRITEN-UHFFFAOYSA-N 0.000 claims 1
- ZJXUHQWGEDEMGC-UHFFFAOYSA-N 3-[[6-(4-chlorophenyl)pyridin-3-yl]oxymethyl]-1-(4-fluorobenzoyl)pyrrolidine-3-carboxylic acid Chemical compound C1CN(C(=O)C=2C=CC(F)=CC=2)CC1(C(=O)O)COC(C=N1)=CC=C1C1=CC=C(Cl)C=C1 ZJXUHQWGEDEMGC-UHFFFAOYSA-N 0.000 claims 1
- 208000005641 Adenomyosis Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010036049 Polycystic ovaries Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000009274 endometriosis of uterus Diseases 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000007106 menorrhagia Diseases 0.000 claims 1
- 208000017708 myomatous neoplasm Diseases 0.000 claims 1
- 210000000754 myometrium Anatomy 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 0 **C(N1CC(*)(CO[Al])CC1)=O Chemical compound **C(N1CC(*)(CO[Al])CC1)=O 0.000 description 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11286908P | 2008-11-10 | 2008-11-10 | |
| US61/112,869 | 2008-11-10 | ||
| PCT/IB2009/054824 WO2010052625A1 (en) | 2008-11-10 | 2009-10-30 | Pyrrolidines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012508225A JP2012508225A (ja) | 2012-04-05 |
| JP2012508225A5 true JP2012508225A5 (enExample) | 2012-12-13 |
Family
ID=41503565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535189A Ceased JP2012508225A (ja) | 2008-11-10 | 2009-10-30 | ピロリジン |
Country Status (31)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| JPWO2013176220A1 (ja) * | 2012-05-25 | 2016-01-14 | 国立大学法人京都大学 | 概日リズム調整 |
| CN110041269A (zh) * | 2019-05-16 | 2019-07-23 | 海门瑞一医药科技有限公司 | 一种2-氯-5-羟基嘧啶的制备方法 |
| WO2022272062A1 (en) | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2106855T3 (es) * | 1991-01-21 | 1997-11-16 | Shionogi & Co | Analogos de 3-benciliden-1-carbamoil-2-pirrolidona. |
| ES2337887T3 (es) * | 2001-12-20 | 2010-04-30 | Merck Serono Sa | Derivados de pirrolidina en calidad de moduladores de prostaglandina. |
| US8039507B2 (en) * | 2005-06-29 | 2011-10-18 | Allergan, Inc. | Therapeutic substituted gamma lactams |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
| DE102006039912A1 (de) * | 2006-08-25 | 2008-03-20 | Bayer Healthcare Ag | Substituierte Spirotetronsäuren und ihre Verwendung |
| MX2009011998A (es) * | 2007-05-10 | 2009-11-19 | Pfizer Ltd | Derivados de azetidina y su uso como antagonistas de prostaglandina e2. |
-
2009
- 2009-10-30 JP JP2011535189A patent/JP2012508225A/ja not_active Ceased
- 2009-10-30 CN CN2009801446055A patent/CN102209710A/zh active Pending
- 2009-10-30 BR BRPI0920924A patent/BRPI0920924A2/pt not_active IP Right Cessation
- 2009-10-30 NZ NZ592311A patent/NZ592311A/xx not_active IP Right Cessation
- 2009-10-30 GE GEAP200912219A patent/GEP20125607B/en unknown
- 2009-10-30 PE PE2011001004A patent/PE20110663A1/es not_active Application Discontinuation
- 2009-10-30 EA EA201100549A patent/EA201100549A1/ru unknown
- 2009-10-30 KR KR1020117013231A patent/KR20110083733A/ko not_active Abandoned
- 2009-10-30 CA CA2741589A patent/CA2741589A1/en not_active Abandoned
- 2009-10-30 AU AU2009312427A patent/AU2009312427B2/en not_active Ceased
- 2009-10-30 EP EP09756838A patent/EP2364296A1/en not_active Withdrawn
- 2009-10-30 WO PCT/IB2009/054824 patent/WO2010052625A1/en not_active Ceased
- 2009-10-30 AP AP2011005728A patent/AP2011005728A0/xx unknown
- 2009-10-30 MX MX2011004903A patent/MX2011004903A/es active IP Right Grant
- 2009-11-06 US US12/613,771 patent/US8278343B2/en not_active Expired - Fee Related
- 2009-11-09 UY UY0001032228A patent/UY32228A/es not_active Application Discontinuation
- 2009-11-09 PA PA20098848001A patent/PA8848001A1/es unknown
- 2009-11-09 TW TW098137955A patent/TW201022234A/zh unknown
- 2009-11-10 AR ARP090104350A patent/AR074314A1/es not_active Application Discontinuation
-
2011
- 2011-04-25 CU CU20110093A patent/CU20110093A7/es unknown
- 2011-04-26 IL IL212490A patent/IL212490A0/en unknown
- 2011-04-26 CR CR20110217A patent/CR20110217A/es unknown
- 2011-04-29 TN TN2011000211A patent/TN2011000211A1/fr unknown
- 2011-05-05 EC EC2011011032A patent/ECSP11011032A/es unknown
- 2011-05-06 SV SV2011003896A patent/SV2011003896A/es unknown
- 2011-05-06 DO DO2011000127A patent/DOP2011000127A/es unknown
- 2011-05-09 NI NI201100092A patent/NI201100092A/es unknown
- 2011-05-09 CL CL2011001034A patent/CL2011001034A1/es unknown
- 2011-05-10 MA MA33829A patent/MA32782B1/fr unknown
- 2011-05-11 CO CO11058068A patent/CO6382112A2/es not_active Application Discontinuation
- 2011-06-09 ZA ZA2011/04310A patent/ZA201104310B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104302626B (zh) | 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途 | |
| JP2014516074A5 (enExample) | ||
| JP2018118992A5 (enExample) | ||
| JP2014139226A5 (enExample) | ||
| JP2016523911A5 (enExample) | ||
| WO2013130855A1 (en) | Indazole derivatives | |
| JP2012525431A5 (enExample) | ||
| JP2018534326A5 (enExample) | ||
| JP2008514643A5 (enExample) | ||
| JP2018535999A5 (enExample) | ||
| JP2010533722A5 (enExample) | ||
| HRP20180546T1 (hr) | Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti | |
| JP2018519323A5 (enExample) | ||
| JP2013522214A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2014531465A5 (enExample) | ||
| RU2008141509A (ru) | Mglur5 модуляторы 1 | |
| JP2018524331A5 (enExample) | ||
| JP2013528591A5 (enExample) | ||
| JP2014001228A (ja) | Ｈ−ｐｇｄｓの阻害剤としてのマルチヘテロアリール化合物及びプロスタグランジンｄ２を介した疾患を治療するための該化合物の使用 | |
| CN105209460A (zh) | 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物 | |
| JP2008517926A5 (enExample) | ||
| JP2007519694A5 (enExample) | ||
| JP2012508225A5 (enExample) | ||
| RU2006131304A (ru) | Производные имидазо[1,2-c]пиримидинилуксусной кислоты |